HEALIOS K.K. ("Healios") is developing next-generation immuno-oncology therapies, with a focus on solid tumors, using NK cells derived from allogeneic iPSCs and whose specific functions have been enhanced with gene editing technology (development code: HLCN061 "eNK cells"). Healios is executing on its strategy to advance its therapeutic programs while leveraging efficient external funding sources involving investments from third parties including project finance, grants and partnerships.